Trial Profile

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Paclitaxel (Primary)
Indications Head and neck cancer; Paranasal-sinus-neoplasms; Squamous cell cancer
Focus Therapeutic Use
Sponsors Fulgent Pharma

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
01 Jun 2026 According to Fulgent pharma release, data from the trial were presented at the American Society of Clinical Oncology (ASCO).
01 Jun 2026 Results presented in the Fulgent pharma Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com